Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 5/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226631 | 0.78 | LOXL2 (0.58) | LOXL2ERCC5FEN1CDK2 | |
| SCHEMBL13191551 | 0.78 | HSD17B1 (0.46) | HDAC6HDAC1KIF11TRPV1DYRK1A | |
| SCHEMBL16886210 | 0.76 | LOXL2 (0.50) | LOXL2ERCC5FEN1STK17B | |
| SCHEMBL30279827 | 0.76 | HSD17B1 (0.49) | HDAC6HDAC1KIF11AKT1CDK2 | |
| SCHEMBL25318136 | 0.75 | CSNK2A1 (0.54) | HDAC6HDAC1KIF11FEN1AKT1 | |
| SCHEMBL4513898 | 0.75 | AOC3 (0.45) | HDAC6HDAC1KIF11FEN1CDK2 | |
| SCHEMBL16892139 | 0.74 | DYRK1A (0.46) | LOXL2STK17BDYRK1A | |
| SCHEMBL8084594 | 0.73 | XDH (0.57) | HDAC6HDAC1KIF11TRPV1AKT1 | |
| SCHEMBL16886211 | 0.73 | LOXL2 (0.50) | HDAC6HDAC1LOXL2ERCC5FEN1 | |
| SCHEMBL3941239 | 0.72 | QPCT (0.49) | HDAC1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| EP-1979347-A2 | POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | PPARG, PPARD, PPARA | HDAC6 254/4885HDAC1 123/4885LOXL2 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.